Lunai Bioworks Inc. (NASDAQ:LNAI) Sees Significant Increase in Short Interest

Lunai Bioworks Inc. (NASDAQ:LNAI) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totaling 1,654,166 shares, a growth of 112.2% from the April 15th total of 779,601 shares. Based on an average trading volume of 3,972,748 shares, the days-to-cover ratio is presently 0.4 days. Currently, 6.9% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC purchased a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks at the end of the most recent reporting period. Institutional investors own 71.41% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Wall Street Zen downgraded Lunai Bioworks from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Lunai Bioworks in a research report on Friday, April 10th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Lunai Bioworks Price Performance

Lunai Bioworks stock traded up $0.01 during mid-day trading on Monday, reaching $0.27. 704,640 shares of the stock traded hands, compared to its average volume of 14,326,196. The stock has a market capitalization of $6.58 million, a PE ratio of 5.44 and a beta of 0.34. Lunai Bioworks has a 12-month low of $0.15 and a 12-month high of $4.50. The business’s 50-day moving average is $0.34 and its 200-day moving average is $0.72.

Lunai Bioworks (NASDAQ:LNAI) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.10) EPS for the quarter. The company had revenue of $0.02 million during the quarter.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.